MCID: LSH001
MIFTS: 66

Leishmaniasis

Categories: Infectious diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leishmaniasis

MalaCards integrated aliases for Leishmaniasis:

Name: Leishmaniasis 11 19 58 75 53 41 2 43 14 16 71 31 33
Post-Kala-Azar Dermal Leishmaniasis 11 71
Post-Kala-Azar Dermal Infectious Disease by Leishmaniasis 11
Post Kala-Azar Dermal Leishmaniasis 11
Leishmaniasis, Cutaneous 71
Cutaneous Leishmaniasis 19
Leishmaniasis, Visceral 71
Visceral Leishmaniasis 19
Leishmania Infection 33
Leishmaniosis 33
Leishmania 33
Kala-Azar 19

Characteristics:


Prevelance:

1-9/1000000 (Europe) 1-5/10000 (Worldwide) 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 11 DOID:9065
ICD9CM 34 085
MeSH 43 D007896
NCIt 49 C34767
SNOMED-CT 68 266206004
ICD10 31 B55 B55.9
MESH via Orphanet 44 D007896
ICD10 via Orphanet 32 B55.0 B55.1 B55.2 more
UMLS via Orphanet 72 C0023281
Orphanet 58 ORPHA507
UMLS 71 C0023281 C0023283 C0023290 more

Summaries for Leishmaniasis

MedlinePlus: 41 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver, and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Leishmaniasis is found in parts of about 88 countries. Most of these countries are in the tropics and subtropics. It is possible but very unlikely that you would get this disease in the United States. But you should be aware of it if you are traveling to the Middle East or parts of Central America, South America, Asia, Africa or southern Europe. Treatment is with medicines that contain antimony, a type of metal, or with strong antibiotics. The best way to prevent the disease is to protect yourself from sand fly bites: Stay indoors from dusk to dawn, when sand flies are the most active Wear long pants and long-sleeved shirts when outside Use insect repellent and bed nets as needed Centers for Disease Control and Prevention

MalaCards based summary: Leishmaniasis, also known as post-kala-azar dermal leishmaniasis, is related to cutaneous leishmaniasis and visceral leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Leishmaniasis is RN7SL1 (RNA Component Of Signal Recognition Particle 7SL1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lidocaine and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, spleen and skin, and related phenotypes are splenomegaly and hepatomegaly

GARD: 19 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of Leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Leishmaniasis is found in parts of the Middle East, Central America, South American, Asia, Africa, and southern Europe. Most of these countries are in the tropics and subtropics. It is possible but very unlikely to get this disease in the United States.

Orphanet: 58 A parasitic disease caused by different species of the genus Leishmania, transmitted through the bite of hematophagous female phlebotomine sand flies. The clinical spectrum ranges from asymptomatic to clinically overt disease which can remain localized to the skin or disseminate to the upper oral and respiratory mucous membranes or throughout the reticulo-endothelial system. Three main clinical syndromes have been described: visceral (or Kala-Azar; with fever, weight loss, hepatosplenomegaly), cutaneous, and mucocutaneous leishmaniasis (cutaneous or mucocutaneous ulceration).

CDC: 2 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a neglected tropical disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

Disease Ontology: 11 A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus Leishmania, which is transmitted by the bite of sand fly (subfamily Phlebotominae).

Wikipedia: 75 Leishmaniasis is a wide array of clinical manifestations caused by parasites of the trypanosome genus... more...

Related Diseases for Leishmaniasis

Diseases related to Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1318)
# Related Disease Score Top Affiliating Genes
1 cutaneous leishmaniasis 32.7 TNF LMLN IL5 IL4 IL2 IL1A
2 visceral leishmaniasis 32.5 TNF TLR2 SLC11A1 LMLN IL5 IL4
3 mucocutaneous leishmaniasis 32.5 TNF SLC11A1 MPI LMLN IL5 IL4
4 chronic rhinitis 31.9 IL5 IL4 IL13
5 aplastic anemia 31.5 TNF IL4 IL1B IL1A IL10 IFNG
6 acquired immunodeficiency syndrome 31.2 TNF RN7SL1 IL2 IL1B IL10 IFNG
7 hemophagocytic lymphohistiocytosis 31.2 TNF IL2 IL1B IL18 IL10 IFNG
8 sporotrichosis 31.2 TNF IL10 IFNG
9 deficiency anemia 31.1 TNF SLC11A1 IL2 IL1B IL10
10 sleeping sickness 31.0 TNF SRM LMLN IL10
11 glomerulonephritis 31.0 TNF IL4 IL1B IL10
12 lymphopenia 30.9 IL4 IL2 IL10 IFNG
13 trypanosomiasis 30.9 TNF TLR2 LMLN IL4 IL2 IL1B
14 exanthem 30.9 TNF IL4 IL2 IL1B IL18 IL10
15 leprosy 3 30.9 TNF TLR2 SLC11A1 IL5 IL4 IL2
16 immune deficiency disease 30.9 TNF TLR2 IL4 IL2 IL1B IL1A
17 chagas disease 30.9 TNF TLR2 SRM IL4 IL2 IL1B
18 histiocytosis 30.9 TNF IL4 IFNG
19 toxoplasmosis 30.9 TNF P2RX7 IL5 IL4 IL1B IL10
20 herpes zoster 30.8 TLR2 IL2 IL10 IFNG
21 erysipelas 30.8 TNF IL2 IL1B
22 spondyloarthropathy 1 30.8 TNF IL1B IL10
23 human immunodeficiency virus infectious disease 30.8 TNF IL4 IL2 IL10 IFNG
24 amebiasis 30.8 TNF TLR2 IL4 IL1B IL10
25 acute pancreatitis 30.8 TNF IL1B IL18 IL10
26 lepromatous leprosy 30.8 TNF TLR2 SLC11A1 IL4 IL2 IL18
27 megaesophagus 30.7 TNF LMLN IL10
28 lymphadenitis 30.7 TNF SLC11A1 IL1B IL18 IL10 IFNGR1
29 allergic disease 30.7 TNF IL5 IL4 IL2 IL1B IL13
30 diarrhea 30.7 TNF IL5 IL2 IL1B IL13 IL10
31 alopecia 30.7 TNF IL4 IL2 IL1B IL1A IFNG
32 uveitis 30.7 TNF IL4 IL2 IL1B IL1A IL10
33 urogenital tuberculosis 30.7 SLC11A1 IFNG
34 filarial elephantiasis 30.7 TNF TLR2 IL5 IL4 IL2 IL13
35 viral infectious disease 30.7 TNF TLR2 IL4 IL2 IL1B IL18
36 kidney disease 30.6 TNF IL2 IL1B IL18 IL10 IFNG
37 panuveitis 30.6 TNF IL1B IL10 IFNG
38 typhoid fever 30.6 TNF SLC11A1 IL1B IL1A IFNGR1 IFNG
39 blepharitis 30.6 TNF IL4 IL2 IL1B IL13
40 cryoglobulinemia 30.6 TNF IL1B IL10 IFNG
41 keratitis, hereditary 30.6 TNF TLR2 IL1B IL10
42 spondylitis 30.6 TNF IL1B IL10 IFNG
43 pneumocystosis 30.6 TNF IL2 IL10 IFNG
44 chickenpox 30.6 TNF IL4 IL2 IL1B IL10 IFNG
45 thrombocytopenia 30.6 TNF TLR2 IL4 IL2 IL1B IL1A
46 bronchopneumonia 30.6 TNF IL1B IL10
47 filariasis 30.6 TNF TLR2 IL5 IL4 IL2 IL13
48 babesiosis 30.6 TNF IL10 HSPA4
49 echinococcosis 30.6 TNF TLR2 IL5 IL10 IFNG
50 tuberculoid leprosy 30.6 TNF TLR2 SLC11A1 IL4 IL2 IL10

Graphical network of the top 20 diseases related to Leishmaniasis:



Diseases related to Leishmaniasis

Symptoms & Phenotypes for Leishmaniasis

Human phenotypes related to Leishmaniasis:

58 30 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001744
2 hepatomegaly 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002240
3 skin ulcer 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0200042
4 abnormal bleeding 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001892
5 papule 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0200034
6 abnormal oral mucosa morphology 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0011830
7 lymphadenopathy 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002716
8 pancytopenia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001876
9 recurrent fever 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001954
10 abnormal macrophage morphology 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0004311
11 rhinitis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012384
12 skin plaque 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0200035
13 night sweats 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0030166
14 anemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001903
15 elevated hepatic transaminase 58 30 Frequent (33%) Frequent (79-30%)
HP:0002910
16 pallor 58 30 Frequent (33%) Frequent (79-30%)
HP:0000980
17 arthralgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002829
18 weight loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0001824
19 hypoalbuminemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0003073
20 increased circulating antibody level 30 Frequent (33%) HP:0010702
21 fatigue 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012378
22 thrombocytopenia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001873
23 anorexia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002039
24 leukopenia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001882
25 increased antibody level in blood 58 Frequent (79-30%)
26 abnormal oral cavity morphology 58 Very frequent (99-80%)

UMLS symptoms related to Leishmaniasis:


fever; pruritus; exanthema

GenomeRNAi Phenotypes related to Leishmaniasis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 IL10 IL18 IL1A IL1B TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 IL10 IL18 IL1B IL2 SRM TNF

MGI Mouse Phenotypes related to Leishmaniasis:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.32 IFNG IL10 IL13 IL18 IL1B IL2
2 nervous system MP:0003631 10.29 HSPA4 IFNG IFNGR1 IL10 IL13 IL18
3 neoplasm MP:0002006 10.22 IFNG IFNGR1 IL10 IL1A IL1B IL2
4 cellular MP:0005384 10.21 HSPA4 IFNG IFNGR1 IL10 IL13 IL18
5 immune system MP:0005387 10.21 IFNG IFNGR1 IL10 IL13 IL18 IL1A
6 digestive/alimentary MP:0005381 10.2 IFNG IFNGR1 IL10 IL13 IL18 IL2
7 cardiovascular system MP:0005385 10.18 IFNG IFNGR1 IL10 IL18 IL1A IL1B
8 liver/biliary system MP:0005370 10.1 IFNG IFNGR1 IL10 IL2 IL4 IL5
9 skeleton MP:0005390 10 IFNG IFNGR1 IL10 IL13 IL1B IL4
10 hematopoietic system MP:0005397 10 IFNG IFNGR1 IL10 IL13 IL18 IL1A
11 respiratory system MP:0005388 9.92 IFNG IL10 IL13 IL2 IL4 IL5
12 mortality/aging MP:0010768 9.8 HSPA4 IFNG IFNGR1 IL10 IL13 IL18
13 integument MP:0010771 9.4 IFNG IFNGR1 IL10 IL13 IL18 IL1A

Drugs & Therapeutics for Leishmaniasis

Drugs for Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965
3
Deoxycholic acid Approved Phase 4 83-44-3 222528
4
Meglumine antimoniate Experimental, Investigational Phase 4 133-51-7
5 Antimony Sodium Gluconate Phase 4
6 Anthelmintics Phase 4
7 Anesthetics Phase 4
8 Anti-Bacterial Agents Phase 4
9 Amebicides Phase 4
10 Liposomal amphotericin B Phase 4
11 Amphotericin B, deoxycholate drug combination Phase 4
12 Gastrointestinal Agents Phase 4
13
Paromomycin Approved, Investigational Phase 3 1263-89-4, 7542-37-2 165580
14
Carbamide peroxide Approved Phase 2, Phase 3 124-43-6
15
Sargramostim Approved, Investigational Phase 3 123774-72-1
16
Aluminum sulfate Approved Phase 2, Phase 3 10043-01-3
17
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
18
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
19
Tocopherol Approved, Investigational Phase 3 1406-66-2
20
BCG vaccine Approved, Investigational Phase 2, Phase 3
21
Azithromycin Approved Phase 2, Phase 3 83905-01-5 447043
22
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
23
Nitric Oxide Approved Phase 3 10102-43-9 145068
24
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 3 59-02-9, 10191-41-0 2116 14985
25
Molgramostim Investigational Phase 3 99283-10-0
26
Tocotrienol Investigational Phase 3 6829-55-6 9929901
27 Vaccines Phase 2, Phase 3
28 Immunologic Factors Phase 3
29 Gentamicins Phase 3
30 Vitamins Phase 3
31 Adjuvants, Immunologic Phase 3
32 Radiation-Protective Agents Phase 2, Phase 3
33 Phosphodiesterase Inhibitors Phase 2, Phase 3
34 Platelet Aggregation Inhibitors Phase 2, Phase 3
35 interferons Phase 3
36 Tocotrienols Phase 3
37 Tocopherols Phase 3
38 Pharmaceutical Solutions Phase 3
39 Antioxidants Phase 3
40 Protective Agents Phase 3
41 Hormones Phase 3
42 Hormone Antagonists Phase 3
43 Cytochrome P-450 Enzyme Inhibitors Phase 3
44 Respiratory System Agents Phase 3
45 Vasodilator Agents Phase 3
46 Bronchodilator Agents Phase 3
47 Anti-Asthmatic Agents Phase 3
48 Endothelium-Dependent Relaxing Factors Phase 3
49 Neurotransmitter Agents Phase 3
50
Pentamidine Approved, Investigational Phase 2 100-33-4 4735

Interventional clinical trials:

(show top 50) (show all 179)
# Name Status NCT ID Phase Drugs
1 Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. Unknown status NCT01566552 Phase 4 AMBISOME
2 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
3 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Infected With Leishmania (Viannia) Braziliensis in Bahia State, Brazil. An Open Uncontrolled Trial. Completed NCT00818818 Phase 4 Meglumine antimoniate
4 Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh Completed NCT03311607 Phase 4 AmBisome
5 Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
6 An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India Completed NCT01661296 Phase 4 Sodium stibogluconate
7 Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis Completed NCT00317980 Phase 4 Meglumine antimoniate
8 A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
9 Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia. Completed NCT01462500 Phase 4 Miltefosine
10 Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B
11 Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes Unknown status NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
12 Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
13 Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
14 Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
15 A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
16 Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
17 Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial Completed NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
18 Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
19 Evaluation of Efficacy of Intra-lesional Injections of Glucantime Once Weekly in Comparison With Twice Weekly in the Treatment of Acute Anthroponotic Cutaneous Leishmaniasis (ACL) Completed NCT04340128 Phase 3 Meglumine antimoniate
20 A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
21 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Completed NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
22 An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) Completed NCT00629031 Phase 3 Paromomycin
23 A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
24 A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
25 Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055) Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
26 Replacement of Insecticides to Control Visceral Leishmaniasis Completed NCT01644682 Phase 3
27 A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
28 Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis Completed NCT00351520 Phase 3 Miltefose
29 Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients Completed NCT00257530 Phase 3 Imiquimod
30 A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
31 A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
32 An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Completed NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
33 A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
34 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
35 Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
36 Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
37 Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study Completed NCT01360762 Phase 3 Pentamidine
38 A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
39 Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
40 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
41 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
42 Treatment of Bolivian Mucosal Leishmaniasis With Miltefosine, Pentavalent Antimony or Liposomal Amphotericin B Recruiting NCT04799236 Phase 3 Group 1: Miltefosine;Group 2: Pentavalent Antimony;Group 3: Liposomal amphotericin B
43 Efficacy and Safety of Thermotherapy in Combination With Miltefosine Compared to Meglumine Antimoniate and Miltefosine Monotherapy for the Treatment of New World Cutaneous Leishmaniasis: A Phase III, Open Label, Multicenter Randomized Trial Recruiting NCT04515186 Phase 3 Meglumine Antimoniate;Miltefosine
44 Randomised, Open Label, Multicentre, Non-inferiority Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan Not yet recruiting NCT04268524 Phase 3
45 Effectiveness, Safety and Feasibility of Thermotherapy With the Hand-held Exothermic Crystallization Thermotherapy for Cutaneous Leishmaniasis (HECT-CL), Device for Cutaneous Leishmaniasis in Quetta, Pakistan Terminated NCT03208543 Phase 3
46 Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
47 Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
48 Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
49 Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
50 EFFICACY AND SAFETY OF A SHORT COURSE OF THE COMBINATION OF MILTEFOSINE AND ANTIMONY TO TREAT CUTANEOUS LEISHMANIASIS IN BOLIVIA Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate

Search NIH Clinical Center for Leishmaniasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Antileishmanial [EPC]
Itraconazole
Ketoconazole
Meglumine
miltefosine
Pentamidine
Pentamidine Isethionate

Cochrane evidence based reviews: leishmaniasis

Genetic Tests for Leishmaniasis

Anatomical Context for Leishmaniasis

Organs/tissues related to Leishmaniasis:

MalaCards : Bone Marrow, Spleen, Skin, Liver, Bone, Endothelial, T Cells

Publications for Leishmaniasis

Articles related to Leishmaniasis:

(show top 50) (show all 39085)
# Title Authors PMID Year
1
Viral endosymbiotic infection of protozoan parasites: How it influences the development of cutaneous leishmaniasis. 62 41
36327251 2022
2
Laboratory diagnostics for human Leishmania infections: a polymerase chain reaction-focussed review of detection and identification methods. 62 41
36335408 2022
3
Synthesis and Anti-Leishmanial Properties of Quinolones Derived from Zanthosimuline. 62 41
36431992 2022
4
T cells specific to leishmania and other nonrelated microbial antigens can migrate to human leishmaniasis skin lesions. 53 62
20107484 2010
5
Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. 53 62
20404924 2010
6
Sequence analysis and PCR-RFLP profiling of the hsp70 gene as a valuable tool for identifying Leishmania species associated with human leishmaniasis in Brazil. 53 62
19913112 2010
7
Anti-iL-10 mAb protection against experimental visceral leishmaniasis via induction of Th1 cytokines and nitric oxide. 53 62
19634715 2009
8
In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment. 53 62
19125672 2009
9
Effects of tropism and virulence of Leishmania parasites on cytokine production by infected human monocytes. 53 62
19040614 2009
10
Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis. 53 62
19037922 2008
11
Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. 53 62
18778366 2008
12
Pentoxifylline down modulate in vitro T cell responses and attenuate pathology in Leishmania and HTLV-I infections. 53 62
18687297 2008
13
Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. 53 62
18444882 2008
14
CD8 cytotoxic T cells in cutaneous leishmaniasis. 53 62
18042173 2007
15
IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. 53 62
17911647 2007
16
Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? 53 62
17614975 2007
17
T-cell responses associated with resistance to Leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis. 53 62
17710308 2007
18
Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. 53 62
17430548 2007
19
Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. 53 62
17395340 2007
20
Circulating nitric oxide and C-reactive protein levels in Indian kala azar patients: correlation with clinical outcome. 53 62
17218153 2007
21
IFNG and IFNGR1 gene polymorphisms and susceptibility to post-kala-azar dermal leishmaniasis in Sudan. 53 62
17136124 2007
22
[CD8+ cytotoxic lymphocytes in cutaneous leishmaniasis]. 53 62
17063826 2006
23
Differential effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production. 53 62
16638143 2006
24
Crystallization and preliminary X-ray analysis of Leishmania major glyoxalase I. 53 62
16511153 2005
25
Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients. 53 62
15853916 2005
26
Natural killer cells and innate immunity to protozoan pathogens. 53 62
15582528 2004
27
Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. 53 62
15569785 2004
28
The role of CD4(+)CD25(+) regulatory T cells in Leishmania infection. 53 62
12943446 2003
29
Polyamine biosynthetic enzymes as drug targets in parasitic protozoa. 53 62
12653650 2003
30
Characterization of the immune response to Leishmania infantum recombinant antigens. 53 62
12593967 2003
31
Up-regulation of Th1-type responses in mucosal leishmaniasis patients. 53 62
12438348 2002
32
Interferon-gamma treatment induces granulomatous tissue reaction in a case of localized cutaneous leishmaniasis. 53 62
12142611 2002
33
Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp. 53 62
11953362 2002
34
Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. 53 62
11544330 2001
35
Unresponsiveness of specific T cells to IL-12 is associated with active cutaneous leishmaniasis owing to Leishmania guyanensis. 53 62
11555399 2001
36
Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis. 53 62
11422202 2001
37
Atypical mucocutaneous leishmaniasis caused by Leishmania braziliensis in an acquired immunodeficiency syndrome patient: T-cell responses and remission of lesions associated with antigen immunotherapy. 53 62
10446016 1999
38
Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. 53 62
9952391 1999
39
T-cell response in human leishmaniasis. 53 62
10065635 1999
40
Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. 53 62
9855627 1998
41
Indications of the protective role of natural killer cells in human cutaneous leishmaniasis in an area of endemicity. 53 62
9596736 1998
42
High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. 53 62
9472662 1998
43
Cytokine profile and pathology in human leishmaniasis. 53 62
9686192 1998
44
[Immunopathology of American tegumentary leishmaniasis]. 53 62
10205916 1998
45
Human_leishmaniasis/cytokines.bahia.br. 53 62
9686193 1998
46
Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production. 53 62
9234779 1997
47
Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-gamma. 53 62
9041358 1997
48
Successful treatment of cutaneous leishmaniasis using systemic interferon-gamma. 53 62
8832954 1996
49
Interferon-gamma in the management of infectious diseases. 53 62
7598304 1995
50
Immunogenetics in the analysis of resistance to intracellular pathogens. 53 62
7495519 1995

Variations for Leishmaniasis

Expression for Leishmaniasis

Search GEO for disease gene expression data for Leishmaniasis.

Pathways for Leishmaniasis

Pathways related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 TNF TLR2 SLC11A1 P2RX7 IL5 IL4
2
Show member pathways
13.87 TNF IL5 IL4 IL2 IL1B IL1A
3
Show member pathways
13.71 TNF IL5 IL4 IL2 IL1B IL1A
4
Show member pathways
13.65 TNF IL5 IL4 IL2 IL1B IL1A
5
Show member pathways
13.53 TNF TLR2 IL4 IL2 IL1B IL1A
6
Show member pathways
13.52 TNF TLR2 IL5 IL4 IL2 IL1B
7
Show member pathways
13.41 TNF IL5 IL4 IL2 IL1B IL1A
8
Show member pathways
13.37 TNF IL5 IL4 IL2 IL1B IL1A
9
Show member pathways
12.88 TNF TLR2 IL2 IL1B IL1A
10
Show member pathways
12.76 IL1A IL1B IL2 TLR2 TNF
11
Show member pathways
12.73 TNF IL1B IL1A IFNGR1 IFNG
12
Show member pathways
12.71 TNF IL2 IL1B IL18 IL10 IFNG
13 12.71 TNF TLR2 IL4 IL2 IL1B IL10
14
Show member pathways
12.7 TNF IL5 IL4 IL2 IL1B IL1A
15
Show member pathways
12.68 TNF TLR2 IL1B IL1A IL18
16
Show member pathways
12.61 TNF TLR2 P2RX7 IL1B IL18
17
Show member pathways
12.57 IL4 IL1B IL1A IL18 IL13
18
Show member pathways
12.55 IFNG IFNGR1 IL1A IL1B IL4 TLR2
19
Show member pathways
12.53 IL5 IL2 IL1B IL1A IL13
20
Show member pathways
12.41 TNF IL1B IL1A IFNGR1 IFNG
21 12.29 IL10 IL13 IL1A IL1B TNF
22
Show member pathways
12.28 TNF IL5 IL4 IL2 IL10 IFNG
23
Show member pathways
12.26 TNF IL4 IL2 IFNG
24 12.25 IFNG IFNGR1 TLR2 TNF
25 12.23 IFNG IFNGR1 IL10 IL13 IL1A IL1B
26
Show member pathways
12.16 TLR2 IL5 IL2 IL1B IL1A IL13
27
Show member pathways
12.13 IL4 IL2 IL1B IL18 IFNG
28 12.12 IFNG IL10 IL2 IL4 IL5 TNF
29 12.1 TNF IL4 IL2 IL1B IL1A IFNG
30 12.09 TNF IL4 IL1B IL1A IL18 IL13
31
Show member pathways
12.04 IL18 IL1A IL1B P2RX7
32
Show member pathways
12.01 IFNG IFNGR1 IL10 IL18 IL1B IL2
33
Show member pathways
11.97 TLR2 IL4 IL1B IFNG
34
Show member pathways
11.96 TNF IL1B IFNGR1 IFNG HSPA4
35 11.94 IFNG IL13 IL2 IL4 IL5
36 11.92 TNF IL2 IL1B IL10 IFNG
37 11.89 TNF IL4 IL2 IL10 IFNG
38 11.88 IFNG IL10 IL13 IL1A IL1B IL2
39 11.87 IFNG IL10 IL2 IL4 IL5
40 11.87 IFNG IFNGR1 IL1B IL2 IL4
41
Show member pathways
11.85 TNF IL5 IL4 IL2 IFNG
42
Show member pathways
11.83 IFNG IFNGR1 IL10 IL13 IL18 IL1A
43
Show member pathways
11.81 TNF IL2 IL1B IL1A IFNG
44 11.81 TNF IL5 IL4 IL1B IL13
45 11.8 IL2 IL10 IFNG
46 11.79 TNF IL1B IL1A IL10
47 11.71 TNF IL1A IL10
48 11.7 IL5 IL4 IL10
49 11.67 TNF TLR2 IL1B IL18 IFNG
50 11.67 TNF IL4 IL2 IL18 IL10 IFNGR1

GO Terms for Leishmaniasis

Biological processes related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.64 IL10 IL18 IL1A IL1B IL2 IL4
2 signal transduction GO:0007165 10.55 IFNG IFNGR1 IL10 IL13 IL18 IL1B
3 inflammatory response GO:0006954 10.36 TNF TLR2 SLC11A1 P2RX7 IL5 IL1B
4 MAPK cascade GO:0000165 10.32 TNF P2RX7 IL1B IL18
5 positive regulation of DNA-binding transcription factor activity GO:0051091 10.3 IL10 IL1B IL5 TNF
6 negative regulation of inflammatory response GO:0050728 10.3 IL4 IL2 IL13 IL10
7 defense response to Gram-positive bacterium GO:0050830 10.3 IL18 IL1B P2RX7 TLR2 TNF
8 positive regulation of tumor necrosis factor production GO:0032760 10.29 TLR2 IL1A IFNGR1 IFNG
9 positive regulation of inflammatory response GO:0050729 10.27 IFNG IL18 IL1B IL2 TLR2 TNF
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.24 TNF TLR2 IL1B IL18
11 positive regulation of type II interferon production GO:0032729 10.22 TNF SLC11A1 IL2 IL1B IL18
12 positive regulation of phagocytosis GO:0050766 10.21 TNF SLC11A1 IL1B IFNG
13 positive regulation of interleukin-6 production GO:0032755 10.21 IFNG IL1A IL1B P2RX7 TLR2 TNF
14 regulation of insulin secretion GO:0050796 10.2 TNF IL1B IFNG
15 positive regulation of nitric oxide biosynthetic process GO:0045429 10.19 TNF IL1B IFNG
16 positive regulation of B cell proliferation GO:0030890 10.19 IL5 IL4 IL2 IL13
17 positive regulation of interleukin-10 production GO:0032733 10.18 TLR2 IL4 IL13
18 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.18 TNF IL1B IL1A
19 positive regulation of gene expression GO:0010628 10.18 TNF TLR2 SLC11A1 P2RX7 IL4 IL1B
20 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.17 TNF IL5 IL10
21 cellular response to organic cyclic compound GO:0071407 10.17 TNF P2RX7 IL1B IL18
22 lipopolysaccharide-mediated signaling pathway GO:0031663 10.17 TNF TLR2 IL1B IL18
23 negative regulation of endothelial cell apoptotic process GO:2000352 10.16 IL4 IL13 IL10
24 positive regulation of mitotic nuclear division GO:0045840 10.16 TNF IL1B IL1A
25 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 10.16 IL4 IL2 IL1B IL1A
26 positive regulation of immunoglobulin production GO:0002639 10.14 IL10 IL13 IL2 IL5
27 positive regulation of amyloid-beta formation GO:1902004 10.13 TNF IFNGR1 IFNG
28 macrophage activation GO:0042116 10.13 SLC11A1 IL4 IL13
29 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10.11 TNF IL1B IFNG
30 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.11 TNF IL1B IL10
31 positive regulation of chemokine production GO:0032722 10.11 TNF TLR2 IL1B IL18 IFNG
32 positive regulation of cytokine production GO:0001819 10.11 IFNG IL10 IL1A IL1B SLC11A1 TNF
33 positive regulation of MHC class II biosynthetic process GO:0045348 10.1 IFNG IL10 IL4
34 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.1 TNF IL4 IL2 IL18 IL13 IFNG
35 positive regulation of prostaglandin secretion GO:0032308 10.08 P2RX7 IL1B IL1A
36 astrocyte activation GO:0048143 10.08 TNF IL1B IFNGR1 IFNG
37 positive regulation of neuroinflammatory response GO:0150078 10.06 IL18 IL1B TNF
38 negative regulation of amyloid-beta clearance GO:1900222 10.05 IFNG IFNGR1 TNF
39 response to lipopolysaccharide GO:0032496 10.03 IL10 IL13 IL1A IL1B P2RX7 SLC11A1
40 neuroinflammatory response GO:0150076 10.02 IL4 IFNG
41 positive regulation of tissue remodeling GO:0034105 10.02 IL2 IL18
42 positive regulation of immature T cell proliferation in thymus GO:0033092 10.02 IL1B IL1A
43 type 2 immune response GO:0042092 10.02 IL4 IL18 IL10
44 negative regulation of cytokine production involved in immune response GO:0002719 10.01 IL10 TNF
45 positive regulation of mononuclear cell migration GO:0071677 10.01 IL4 TNF
46 positive regulation of fever generation GO:0031622 10.01 TNF IL1B
47 sequestering of triglyceride GO:0030730 9.99 IL1B TNF
48 regulation of isotype switching GO:0045191 9.99 IL10 IL4
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.99 TNF IL1B IFNG
50 fever generation GO:0001660 9.98 IL1A IL1B

Molecular functions related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 TNF IL5 IL4 IL2 IL1B IL1A

Sources for Leishmaniasis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....